Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gastric Cancer

  Free Subscription


Articles published in Eur J Surg Oncol

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    September 2017
  1. GALLEBERG RB, Knigge U, Tiensuu Janson E, Vestermark LW, et al
    Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Eur J Surg Oncol. 2017;43:1682-1689.
    PubMed     Text format     Abstract available


  2. TOMASELLO G, Petrelli F, Ghidini M, Pezzica E, et al
    Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
    Eur J Surg Oncol. 2017;43:1607-1616.
    PubMed     Text format     Abstract available


    August 2017
  3. KATAOKA K, Deleersnijder A, Lordick F
    Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?
    Eur J Surg Oncol. 2017 Aug 30. pii: S0748-7983(17)30644.
    PubMed     Text format     Abstract available


  4. RONELLENFITSCH U, Schwarzbach M, Hofheinz R, Kienle P, et al
    Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
    Eur J Surg Oncol. 2017;43:1550-1558.
    PubMed     Text format     Abstract available


    July 2017
  5. BUSWEILER LA, Henneman D, Dikken JL, Fiocco M, et al
    Failure-to-rescue in patients undergoing surgery for esophageal or gastric cancer.
    Eur J Surg Oncol. 2017 Jul 29. pii: S0748-7983(17)30589.
    PubMed     Text format     Abstract available


    June 2017
  6. HUBNER M, Grass F, Teixeira-Farinha H, Pache B, et al
    Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical aspects.
    Eur J Surg Oncol. 2017;43:1102-1109.
    PubMed     Text format     Abstract available


    May 2017
  7. REIM D, Choi YS, Yoon HM, Park B, et al
    Alpha-fetoprotein is a significant prognostic factor for gastric cancer: Results from a propensity score matching analysis after curative resection.
    Eur J Surg Oncol. 2017 May 3. pii: S0748-7983(17)30447.
    PubMed     Text format     Abstract available


    April 2017
  8. MILONE M, Elmore U, Musella M, Parise P, et al
    Safety and efficacy of laparoscopic wedge gastrectomy for large gastrointestinal stromal tumors.
    Eur J Surg Oncol. 2017;43:796-800.
    PubMed     Text format     Abstract available


  9. KESHAVA HB, Rosen JE, DeLuzio MR, Kim AW, et al
    "What if I do nothing?" The natural history of operable cancer of the alimentary tract.
    Eur J Surg Oncol. 2017;43:788-795.
    PubMed     Text format     Abstract available


    March 2017
  10. BOULIARIS K, Rachiotis G, Diamantis A, Christodoulidis G, et al
    Lymph node ratio as a prognostic factor in gastric cancer patients following D1 resection. Comparison with the current TNM staging system.
    Eur J Surg Oncol. 2017 Mar 27. pii: S0748-7983(17)30430.
    PubMed     Text format     Abstract available


  11. SASAKO M
    Is there role for laparoscopic gastrectomy for advanced gastric cancer.
    Eur J Surg Oncol. 2017 Mar 8. pii: S0748-7983(17)30363.
    PubMed     Text format    


  12. CHOI YY, Cheong JH
    Beyond precision surgery: Molecularly motivated precision care for gastric cancer.
    Eur J Surg Oncol. 2017 Mar 1. pii: S0748-7983(17)30360.
    PubMed     Text format     Abstract available


    February 2017
  13. NORERO E, Vega EA, Diaz C, Cavada G, et al
    Improvement in postoperative mortality in elective gastrectomy for gastric cancer: Analysis of predictive factors in 1066 patients from a single centre.
    Eur J Surg Oncol. 2017 Feb 10. pii: S0748-7983(17)30050.
    PubMed     Text format     Abstract available


  14. CLIMENT M, Munarriz M, Blazeby JM, Dorcaratto D, et al
    Weight loss and quality of life in patients surviving 2 years after gastric cancer resection.
    Eur J Surg Oncol. 2017 Feb 9. pii: S0748-7983(17)30337.
    PubMed     Text format     Abstract available


  15. BOURAS G, Markar SR, Burns EM, Huddy JR, et al
    The psychological impact of symptoms related to esophagogastric cancer resection presenting in primary care: A national linked database study.
    Eur J Surg Oncol. 2017;43:454-460.
    PubMed     Text format     Abstract available


    January 2017
  16. KAITO A, Kinoshita T, Shitara K, Shibasaki H, et al
    Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
    Eur J Surg Oncol. 2017 Jan 29. pii: S0748-7983(17)30058.
    PubMed     Text format     Abstract available


  17. LEHMANN K, Eshmuminov D, Bauerfeind P, Gubler C, et al
    18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma.
    Eur J Surg Oncol. 2017;43:196-202.
    PubMed     Text format     Abstract available


  18. KIM S, Paget-Bailly S, Messager M, Nguyen T, et al
    Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
    Eur J Surg Oncol. 2017;43:218-225.
    PubMed     Text format     Abstract available


  19. PARRY K, van Rossum PS, Haj Mohammad N, Ruurda JP, et al
    The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
    Eur J Surg Oncol. 2017;43:226-233.
    PubMed     Text format     Abstract available


    December 2016
  20. TU RH, Lin JX, Zheng CH, Li P, et al
    Development of a nomogram for predicting the risk of anastomotic leakage after a gastrectomy for gastric cancer.
    Eur J Surg Oncol. 2016 Dec 20. pii: S0748-7983(16)31052.
    PubMed     Text format     Abstract available


  21. PARK JM, Kim HI, Han SU, Yang HK, et al
    Who may benefit from robotic gastrectomy?: A subgroup analysis of multicenter prospective comparative study data on robotic versus laparoscopic gastrectomy.
    Eur J Surg Oncol. 2016;42:1944-1949.
    PubMed     Text format     Abstract available


    October 2016
  22. XIE JW, Sun YQ, Feng CY, Zheng CH, et al
    Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma.
    Eur J Surg Oncol. 2016;42:1464-70.
    PubMed     Text format     Abstract available


  23. MOSQUERA C, Koutlas NJ, Fitzgerald TL
    Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Eur J Surg Oncol. 2016;42:1471-7.
    PubMed     Text format     Abstract available


    September 2016
  24. LEE JH, Kang JW, Nam BH, Cho GS, et al
    Correlation between lymph node count and survival and a reappraisal of lymph node ratio as a predictor of survival in gastric cancer: A multi-institutional cohort study.
    Eur J Surg Oncol. 2016 Sep 30. pii: S0748-7983(16)30895.
    PubMed     Text format     Abstract available


  25. LOU N, Chi CH, Chen XD, Zhou CJ, et al
    Sarcopenia in overweight and obese patients is a predictive factor for postoperative complication in gastric cancer: A prospective study.
    Eur J Surg Oncol. 2016 Sep 17. pii: S0748-7983(16)30894.
    PubMed     Text format     Abstract available


  26. MESSAGER M, de Steur W, Boelens PG, Jensen LS, et al
    Description and analysis of clinical pathways for oesophago-gastric adenocarcinoma, in 10 European countries (the EURECCA upper gastro intestinal group - European Registration of Cancer Care).
    Eur J Surg Oncol. 2016;42:1432-47.
    PubMed     Text format     Abstract available


    August 2016
  27. KOMATSU S, Ichikawa D, Nishimura M, Kosuga T, et al
    Evaluation of prognostic value and stage migration effect using positive lymph node ratio in gastric cancer.
    Eur J Surg Oncol. 2016 Aug 21. pii: S0748-7983(16)30839.
    PubMed     Text format     Abstract available


  28. WU HT, Li Y
    Reply to: Re: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center, Eur J Surg Oncol (2016).
    Eur J Surg Oncol. 2016 Aug 12. pii: S0748-7983(16)30638.
    PubMed     Text format    


  29. MARANO L, Marrelli D, Roviello F
    Focus on research: Nodal dissection for gastric cancer - A dilemma worthy of King Solomon!
    Eur J Surg Oncol. 2016 Aug 11. pii: S0748-7983(16)30838.
    PubMed     Text format    


  30. KIM JW, Choi SH
    Re: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center, Eur J Surg Oncol (2016).
    Eur J Surg Oncol. 2016 Aug 11. pii: S0748-7983(16)30639.
    PubMed     Text format    


  31. MAKUUCHI R, Sugisawa N, Kaji S, Hikage M, et al
    Enhanced recovery after surgery for gastric cancer and an assessment of preoperative carbohydrate loading.
    Eur J Surg Oncol. 2016 Aug 10. pii: S0748-7983(16)30834.
    PubMed     Text format     Abstract available


  32. CAPELLI L, Petracci E, Quagliuolo V, Saragoni L, et al
    Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.
    Eur J Surg Oncol. 2016;42:1206-14.
    PubMed     Text format     Abstract available


  33. KULIG P, Sierzega M, Pach R, Kolodziejczyk P, et al
    Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location.
    Eur J Surg Oncol. 2016;42:1215-21.
    PubMed     Text format     Abstract available


  34. O'NEILL AC, Shinagare AB, Kurra V, Tirumani SH, et al
    Assessment of metastatic risk of gastric GIST based on treatment-naive CT features.
    Eur J Surg Oncol. 2016;42:1222-8.
    PubMed     Text format     Abstract available


    July 2016
  35. RAMOS RF, Scalon FM, Scalon MM, Dias DI, et al
    Staging laparoscopy in gastric cancer to detect peritoneal metastases: A systematic review and meta-analysis.
    Eur J Surg Oncol. 2016 Jul 9. pii: S0748-7983(16)30633.
    PubMed     Text format     Abstract available


    June 2016
  36. RAUSEI S, Ruspi L, Rosa F, Morgagni P, et al
    Extended lymphadenectomy in elderly and/or highly co-morbid gastric cancer patients: A retrospective multicenter study.
    Eur J Surg Oncol. 2016 Jun 1. pii: S0748-7983(16)30153.
    PubMed     Text format     Abstract available


  37. YANG Y, Gao P, Song Y, Sun J, et al
    The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: A meta-analysis.
    Eur J Surg Oncol. 2016 Jun 1. pii: S0748-7983(16)30180.
    PubMed     Text format     Abstract available


    May 2016
  38. WU HT, Peng KW, Ji ZH, Sun JH, et al
    Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
    Eur J Surg Oncol. 2016 May 3. pii: S0748-7983(16)30114.
    PubMed     Text format     Abstract available


    April 2016
  39. TIBERIO GA, Ministrini S, Gardini A, Marrelli D, et al
    Factors influencing survival after hepatectomy for metastases from gastric cancer.
    Eur J Surg Oncol. 2016 Apr 19. pii: S0748-7983(16)30047.
    PubMed     Text format     Abstract available


  40. COCCOLINI F, Catena F, Glehen O, Yonemura Y, et al
    Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis.
    Eur J Surg Oncol. 2016 Apr 19. pii: S0748-7983(16)30053.
    PubMed     Text format     Abstract available


  41. YONEMURA Y, Canbay E, Li Y, Coccolini F, et al
    A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent.
    Eur J Surg Oncol. 2016 Apr 9. pii: S0748-7983(16)30025.
    PubMed     Text format     Abstract available


    March 2016
  42. KOIZUMI N, Harada Y, Beika M, Minamikawa T, et al
    Highly sensitive fluorescence detection of metastatic lymph nodes of gastric cancer with photo-oxidation of protoporphyrin IX.
    Eur J Surg Oncol. 2016 Mar 31. pii: S0748-7983(16)00381.
    PubMed     Text format     Abstract available


  43. YAMASHITA K, Hosoda K, Ema A, Watanabe M, et al
    Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancer.
    Eur J Surg Oncol. 2016 Mar 15. pii: S0748-7983(16)00379.
    PubMed     Text format     Abstract available


  44. PARRY K, Haverkamp L, Bruijnen RC, Siersema PD, et al
    Staging of adenocarcinoma of the gastroesophageal junction.
    Eur J Surg Oncol. 2016;42:400-6.
    PubMed     Text format     Abstract available


    January 2016
  45. MORITA S, Fukagawa T, Fujiwara H, Katai H, et al
    The clinical significance of para-aortic nodal dissection for advanced gastric cancer.
    Eur J Surg Oncol. 2016 Jan 26. pii: S0748-7983(16)00044.
    PubMed     Text format     Abstract available


    December 2015
  46. ZHOU CJ, Chen FF, Zhuang CL, Pang WY, et al
    Feasibility of radical gastrectomy for elderly patients with gastric cancer.
    Eur J Surg Oncol. 2015 Dec 6. pii: S0748-7983(15)00894.
    PubMed     Text format     Abstract available


    November 2015
  47. MARANO L, Polom K, Patriti A, Roviello G, et al
    Surgical management of advanced gastric cancer: An evolving issue.
    Eur J Surg Oncol. 2015 Nov 14. pii: S0748-7983(15)00840.
    PubMed     Text format     Abstract available


    October 2015
  48. NORERO E, Bustos M, Herrera ME, Cerda J, et al
    Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
    Eur J Surg Oncol. 2015 Oct 24. pii: S0748-7983(15)00825.
    PubMed     Text format     Abstract available


  49. HAVERKAMP L, Ruurda JP, Offerhaus GJ, Weijs TJ, et al
    Laparoscopic gastrectomy in Western European patients with advanced gastric cancer.
    Eur J Surg Oncol. 2015 Oct 22. pii: S0748-7983(15)00793.
    PubMed     Text format     Abstract available


  50. GLATZ T, Bronsert P, Schafer M, Kulemann B, et al
    Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Eur J Surg Oncol. 2015;41:1300-7.
    PubMed     Text format     Abstract available


  51. MINE S, Kurokawa Y, Takeuchi H, Kishi K, et al
    Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors.
    Eur J Surg Oncol. 2015;41:1348-53.
    PubMed     Text format     Abstract available


    September 2015
  52. MESSAGER M, de Steur WO, van Sandick JW, Reynolds J, et al
    Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: A survey from the EURECCA Upper GI Group (EUropean REgistration of Cancer CAre).
    Eur J Surg Oncol. 2015 Sep 30. pii: S0748-7983(15)00792.
    PubMed     Text format     Abstract available


  53. CLIMENT M, Hidalgo N, Vidal O, Puig S, et al
    Postoperative complications do not impact on recurrence and survival after curative resection of gastric cancer.
    Eur J Surg Oncol. 2015 Sep 3. pii: S0748-7983(15)00735.
    PubMed     Text format     Abstract available


  54. BARCHI LC, Yagi OK, Jacob CE, Mucerino DR, et al
    Predicting recurrence after curative resection for gastric cancer: External validation of the Italian Research Group for Gastric Cancer (GIRCG) prognostic scoring system.
    Eur J Surg Oncol. 2015 Sep 3. pii: S0748-7983(15)00736.
    PubMed     Text format     Abstract available


    July 2015
  55. YAMASHITA K, Ushiku H, Katada N, Hosoda K, et al
    Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
    Eur J Surg Oncol. 2015 Jul 29. pii: S0748-7983(15)00479.
    PubMed     Text format     Abstract available



  56. Retraction notice to "Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: An updated meta-analysis of randomized controlled trials" [Eur J Surg Oncol 40 (10) (October 2014) 1321-1330].
    Eur J Surg Oncol. 2015;41:953.
    PubMed     Text format    


  57. GOH BK, Goh YC, Eng AK, Chan WH, et al
    Outcome after laparoscopic versus open wedge resection for suspected gastric gastrointestinal stromal tumors: A matched-pair case-control study.
    Eur J Surg Oncol. 2015;41:905-10.
    PubMed     Text format     Abstract available


    June 2015
  58. WANG Y, Shen C, Ge J, Duan H, et al
    Regular aspirin use and stomach cancer risk in China.
    Eur J Surg Oncol. 2015;41:801-4.
    PubMed     Text format     Abstract available


    May 2015
  59. SCHMIDT T, Alldinger I, Blank S, Klose J, et al
    Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.
    Eur J Surg Oncol. 2015 May 29. pii: S0748-7983(15)00436.
    PubMed     Text format     Abstract available


  60. KINOSHITA J, Fushida S, Tsukada T, Oyama K, et al
    Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
    Eur J Surg Oncol. 2015 May 15. pii: S0748-7983(15)00429.
    PubMed     Text format     Abstract available


  61. YAMAGUCHI H, Kitayama J, Emoto S, Ishigami H, et al
    Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
    Eur J Surg Oncol. 2015 May 8. pii: S0748-7983(15)00415.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: